Promoting Genomics Research and Development in Africa

The African Center for Translational Genomics (ACTG) is an initiative established by 54gene for the advancement of genomic research, knowledge and resources within the African continent.

The ACTG is aimed at growing resources within the continent to enhance Africa's competitive advantage globally as it relates to genomics and disease.

It will also facilitate genomics research by ensuring collaborators under the initiative are provided access to cutting edge technologies that will boost research productivity. Insights generated from these research activities will answer pertinent questions about drivers of disease that are prevalent in Africa.

Our core objectives are embedded in the following areas:

Empowering Scientists

Empowering the next generation of African genomic scientists through the provision and implementation of grants, fellowships, internships and training for medical researchers, trainees and students enhancing Africa's competitive advantage, globally.

Translational Research

Enabling better health outcomes by powering the discovery of disease variants which will significantly improve responses to drugs. This will ensure better efficacy of medicines for Africans and the greater global population.

Precision Medicine

Enhancing therapy on the African continent by enabling individualized and precise care that utilises patient unique genetic identity to develop new targets to medicine.

Non-Communicable Diseases – Genetic Heritage Study (NCD-GHS) Consortium

About the NCD-GHS:

There is an imminent need to study and understand the mysteries of the African genome now more than ever. With the growing infusion of precision medicine into the healthcare system, the lack of genetic databases for African populations and people of African ancestry has revealed a large divide that persists between the African demographic and efficacious medical treatment and diagnostics.

In a one of a kind initiative, 54gene, with collaborators from the Nigerian Institute of Medical Research (NIMR) and the National Biotechnology Development Agency’s Center for Genomic Research & Innovation (NABDA-CGRI), have formed the Non Communicable Diseases GeneticHeritage Study (NCD-GHS) Consortium. This is a Public-Private partnership that seeks to harness the genomic potential of the ethnolinguistic diversity of Nigerians towards better understanding of the determinants of NCDs and development of new solutions to improve their management for the benefit of Africans and other global populations.

With its launch, the consortium would provide leadership and facilitate the completion of the Genetic Profiling for Non-Communicable Diseases Study (also called the 54Gene Heritage Study or 54GHS in short), which was started by 54gene and is ongoing, as well as the implementation of the Nigeria Cardiometabolic Diseases Genetic (NiCGen) Study. It is expectedthat with these two studies combined, genomic data from at least 100,000 Nigerians would be unlocked for knowledge creation and development of insights that would facilitate precision medicine and translational research that would impact people’s health significantly.

The work of the Consortium is being funded by the African Center for Translational Genetics (ACTG) with support from 54gene. The African Center for Translational Genetics (ACTG) is a not-for-profit entity with funding from 54gene Inc as part of its vision to democratize precision medicine. The objectives of the centre are to empower the next generation of African genomic scientists through the provision and implementation of grants, fellowships, and internships; enable better health outcomes by powering the discovery of disease variants which will significantly improve responses to drugs especially among African populations, and enhance therapy on the African continent by enabling individualized and precise care that utilises patient unique genetic identity to develop new targets for medicines.

Contact

To learn more about the African Center for Translational Genomics please fill in your details below. We look forward to hearing from you.